{"name":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","slug":"jiangsu-aosaikang-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ASK120067","genericName":"ASK120067","slug":"ask120067","indication":"Other","status":"phase_3"},{"name":"ASKB1202","genericName":"ASKB1202","slug":"askb1202","indication":"Other","status":"phase_1"},{"name":"ASKC202","genericName":"ASKC202","slug":"askc202","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ASKC202+ Limertinib","genericName":"ASKC202+ Limertinib","slug":"askc202-limertinib","indication":"EGFR-mutant non-small cell lung cancer with acquired resistance to prior EGFR inhibitors","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ASK120067;itraconazole","genericName":"ASK120067;itraconazole","slug":"ask120067-itraconazole","indication":"Fungal infections","status":"phase_1"}]}],"pipeline":[{"name":"ASK120067","genericName":"ASK120067","slug":"ask120067","phase":"phase_3","mechanism":"ASK120067 is an investigational therapeutic agent in phase 3 development by Jiangsu Aosaikang Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.","indications":[],"catalyst":""},{"name":"ASKC202+ Limertinib","genericName":"ASKC202+ Limertinib","slug":"askc202-limertinib","phase":"phase_3","mechanism":"ASKC202 is a bispecific antibody targeting EGFR and c-MET, combined with limertinib, a third-generation EGFR tyrosine kinase inhibitor, to overcome resistance in EGFR-mutant lung cancer.","indications":["EGFR-mutant non-small cell lung cancer with acquired resistance to prior EGFR inhibitors"],"catalyst":""},{"name":"ASK120067;itraconazole","genericName":"ASK120067;itraconazole","slug":"ask120067-itraconazole","phase":"phase_1","mechanism":"Azole antifungal agent","indications":["Fungal infections"],"catalyst":""},{"name":"ASKB1202","genericName":"ASKB1202","slug":"askb1202","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ASKC202","genericName":"ASKC202","slug":"askc202","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxNQzFBdWhLa08wS28yRGZsbnpYMEtTYmZhb3lLOWg3ZDhYQmdDVzJBN2J1Qkc0VERIVlBTSjk2SkxIY29vSkZmX284UTdMZHdPSFR4Wlh1RS04TWlOaVFhQWdnamJMS19HbXlCcjR6TFhwRHZPQWlBUFkyTHFLSkJFaUZfaEc0ODNYbGI3R05Ud3M1bUJPb215ZTM2eDVyazFLVVJtZmpNNGU3NUFnM2JSSlc2V21oUzdjOFc3XzRJV1BpZkFsM1JjSVZfaFNVb0VkODQ3QWZhMmlDa1d2cWl4cURHd2hERkpsVHRtenl5YkNCbHUxQ2oyZjlWTG1zVjlpLUtyNmFORlN6NzdrV0VTbzZOODl4ZkNWaDJ1RkVrTXE3cDI4Vk4zT3dzWHlMWklHWlNUTzc2aC0?oc=5","date":"2026-02-12","type":"trial","source":"GlobeNewswire","summary":"Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - GlobeNewswire","headline":"Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxNRGNJOEMxbXhpMUJEc0lsLTZCNTB0YzY1aUd2eDAwcy1HbFJoREZ0dnYyVzhHcG5QR2tPLUk4WGFxNlVBbV9OOXc0dHJycHN3bUVMLTBxb3Zwb0pLc2dObEtxSzh4LTZpSHFYcU1uN1RyM3Z6MUZHU1VxWDVYNTA2clh2Qng2elR2Xy1MYXoxSUxCUTNlaDVvVlg2TjJsZC1tcTQ0MHprd2dBY0J2Vi1yeHFzZnFoQkNsbkwwaHZaaThFQW9iLUpBRlZ5TUtZS1lBRkF3U1BOQ0tIRGdrSC0yd1lnWFhSY2NjY1U3OHJZRzNpMU1Bd1JiU3FaRlhUM1REVFh4eWhIRzZkcjcyUVk5dA?oc=5","date":"2025-12-29","type":"deal","source":"GlobeNewswire","summary":"Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - GlobeNewswire","headline":"Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNMUtnaTJxNVpia1dCaW5TQjVuUHJWNVVzWlowWkI4dTBqa09mcGVqbm5CTjQ4cDA4b185ckJsQ1p6WUhnNm45NjBjbXJ3MDBiWUlyMWwweVE1UWRra1pmSTFNTlJZZW9FYXludjJkMFlvSXBLenBfUEtCTHJNNGU2TTFJRGlVTE5UeFlBWHBKV0NZMkNQX29RSXJTMmxzdEpJN3h5b0F4d2J2UTQwTlRiWndIXzZ0bzZyTG9TWA?oc=5","date":"2025-12-29","type":"deal","source":"Stock Titan","summary":"Deal worth up to $230M grants China rights to new RAS cancer drug - Stock Titan","headline":"Deal worth up to $230M grants China rights to new RAS cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQbzg4RE9WSmhCYlJvaDV5ZzBVR202aExKaVNvWHIwTzU2TEpsc1p4NDBlMTNET29QQmdJLUlEbTBJMkp3R2x6SnlCaTAyTUduNEpZM0NrMkNvUm9vdlZ0OV9pNHdxWmFFOHh5OHNxSE9zY2ZnaUpTc2JiblNIUTlZR0hOVklRY2lvak5kTjdnN0FldG5CbVU2dkF5S09vSkVLVmR3WEg3OFQxRXFRMTJqbA?oc=5","date":"2024-11-16","type":"pipeline","source":"Gilbert + Tobin","summary":"Pharmaceuticals & Medical Product Sector: GCR Competition Law Developments in APAC | G+T - Gilbert + Tobin","headline":"Pharmaceuticals & Medical Product Sector: GCR Competition Law Developments in APAC | G+T - Gilbert + Tobin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOOERHRlpUVWJZQnhXMzRfVmZXMmtGcFJyNG5IS0piTVJkQ0FKS1d1NWJ5ZnotVkNSY1UwQ2x1ZjVlLV9QSXZZSG1mVXNmOGJBbXdPMVlwWXlfQlNpeHhZbG5IRzZPbGdYTldQTHpJakZnbjdqWUszSnh6Q1BXWVhST1phdGhfOFJvN25peTFQUjJQWmRYb1FRR05lV2xxb2RJZXc?oc=5","date":"2021-12-06","type":"trial","source":"globaldata.com","summary":"Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition - globaldata.com","headline":"Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE9FdUtmSjJnRkp6OEhLdXg3SDlFYmw2TmI2M0c2RGEzWnVhY184THBKZlNCVldDYk9GU0owaTZXcFp3QTJvVGlrbzBuejdSUTVDSl9IYndZZ3lrRm9iakwtcGE4TQ?oc=5","date":"2019-12-24","type":"earnings","source":"Straits Research","summary":"Oxaliplatin Market Size, Growth & Revenue Analysis Report | 2033 - Straits Research","headline":"Oxaliplatin Market Size, Growth & Revenue Analysis Report | 2033","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":2,"phase_1":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}